vs

Side-by-side financial comparison of CME Group (CME) and Solstice Advanced Materials Inc. (SOLS). Click either name above to swap in a different company.

CME Group is the larger business by last-quarter revenue ($1.9B vs $991.0M, roughly 1.9× Solstice Advanced Materials Inc.). Solstice Advanced Materials Inc. runs the higher net margin — 8.6% vs 0.1%, a 8.5% gap on every dollar of revenue. On growth, CME Group posted the faster year-over-year revenue change (14.5% vs 10.0%).

CME Group Inc. is an American financial services company based in Chicago, Illinois. It operates financial derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX), and the Commodity Exchange (COMEX). The company owns 27% of S&P Dow Jones Indices. It is the world's largest operator of financial derivatives exchanges. Its exchanges are platforms for trading in agricultural products, currencies, energy, i...

Solstice Advanced Materials Inc. is a specialty advanced materials provider that develops, produces and distributes high-performance functional materials for renewable energy systems, consumer electronics, industrial manufacturing and advanced automotive sectors. The company focuses on material solutions that boost product durability, energy efficiency and operational performance for its global clients.

CME vs SOLS — Head-to-Head

Bigger by revenue
CME
CME
1.9× larger
CME
$1.9B
$991.0M
SOLS
Growing faster (revenue YoY)
CME
CME
+4.5% gap
CME
14.5%
10.0%
SOLS
Higher net margin
SOLS
SOLS
8.5% more per $
SOLS
8.6%
0.1%
CME

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
CME
CME
SOLS
SOLS
Revenue
$1.9B
$991.0M
Net Profit
$1.2M
$85.0M
Gross Margin
Operating Margin
0.1%
Net Margin
0.1%
8.6%
Revenue YoY
14.5%
10.0%
Net Profit YoY
20.7%
-36.6%
EPS (diluted)
$0.53

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CME
CME
SOLS
SOLS
Q1 26
$1.9B
$991.0M
Q4 25
$1.6B
Q3 25
$1.5B
$969.0M
Q2 25
$1.7B
Q1 25
$1.6B
Q4 24
$1.5B
Q3 24
$1.6B
$907.0M
Q2 24
$1.5B
Net Profit
CME
CME
SOLS
SOLS
Q1 26
$1.2M
$85.0M
Q4 25
$1.2B
Q3 25
$908.0M
$-35.0M
Q2 25
$1.0B
Q1 25
$956.2M
Q4 24
$874.6M
Q3 24
$912.8M
$152.0M
Q2 24
$883.2M
Gross Margin
CME
CME
SOLS
SOLS
Q1 26
Q4 25
Q3 25
32.0%
Q2 25
Q1 25
Q4 24
Q3 24
36.6%
Q2 24
Operating Margin
CME
CME
SOLS
SOLS
Q1 26
0.1%
Q4 25
61.8%
Q3 25
63.3%
17.9%
Q2 25
66.7%
Q1 25
67.5%
Q4 24
62.1%
Q3 24
64.6%
21.7%
Q2 24
65.3%
Net Margin
CME
CME
SOLS
SOLS
Q1 26
0.1%
8.6%
Q4 25
71.7%
Q3 25
59.1%
-3.6%
Q2 25
60.6%
Q1 25
58.2%
Q4 24
57.3%
Q3 24
57.6%
16.8%
Q2 24
57.6%
EPS (diluted)
CME
CME
SOLS
SOLS
Q1 26
$0.53
Q4 25
$3.24
Q3 25
$2.49
Q2 25
$2.81
Q1 25
$2.62
Q4 24
$2.40
Q3 24
$2.50
Q2 24
$2.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CME
CME
SOLS
SOLS
Cash + ST InvestmentsLiquidity on hand
$2.4B
$642.0M
Total DebtLower is stronger
$3.4B
$2.0B
Stockholders' EquityBook value
$1.5B
Total Assets
$202.0B
$5.7B
Debt / EquityLower = less leverage
1.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CME
CME
SOLS
SOLS
Q1 26
$2.4B
$642.0M
Q4 25
$4.5B
Q3 25
$2.6B
$417.0M
Q2 25
$2.1B
Q1 25
$1.5B
Q4 24
$3.0B
Q3 24
$2.4B
Q2 24
$1.9B
Total Debt
CME
CME
SOLS
SOLS
Q1 26
$3.4B
$2.0B
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
CME
CME
SOLS
SOLS
Q1 26
$1.5B
Q4 25
$28.7B
Q3 25
$28.2B
$3.2B
Q2 25
$27.7B
Q1 25
$27.0B
Q4 24
$26.5B
Q3 24
$28.2B
$3.2B
Q2 24
$27.6B
Total Assets
CME
CME
SOLS
SOLS
Q1 26
$202.0B
$5.7B
Q4 25
$198.4B
Q3 25
$187.1B
$5.2B
Q2 25
$179.9B
Q1 25
$157.8B
Q4 24
$137.4B
Q3 24
$137.8B
Q2 24
$123.4B
Debt / Equity
CME
CME
SOLS
SOLS
Q1 26
1.34×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CME
CME
SOLS
SOLS
Operating Cash FlowLast quarter
$199.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
7.6%
Cash ConversionOCF / Net Profit
2.34×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CME
CME
SOLS
SOLS
Q1 26
$199.0M
Q4 25
$1.1B
Q3 25
$968.1M
$289.0M
Q2 25
$1.1B
Q1 25
$1.1B
Q4 24
$1.0B
Q3 24
$1.0B
Q2 24
$776.9M
Free Cash Flow
CME
CME
SOLS
SOLS
Q1 26
Q4 25
$1.1B
Q3 25
$949.7M
$41.0M
Q2 25
$1.0B
Q1 25
$1.1B
Q4 24
$991.7M
Q3 24
$973.2M
Q2 24
$758.7M
FCF Margin
CME
CME
SOLS
SOLS
Q1 26
Q4 25
66.8%
Q3 25
61.8%
4.2%
Q2 25
61.5%
Q1 25
67.1%
Q4 24
65.0%
Q3 24
61.4%
Q2 24
49.5%
Capex Intensity
CME
CME
SOLS
SOLS
Q1 26
7.6%
Q4 25
2.0%
Q3 25
1.2%
25.6%
Q2 25
1.1%
Q1 25
0.9%
Q4 24
1.7%
Q3 24
1.9%
Q2 24
1.2%
Cash Conversion
CME
CME
SOLS
SOLS
Q1 26
2.34×
Q4 25
0.96×
Q3 25
1.07×
Q2 25
1.03×
Q1 25
1.17×
Q4 24
1.16×
Q3 24
1.10×
Q2 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CME
CME

Segment breakdown not available.

SOLS
SOLS

Product sales$915.0M92%
Service sales$77.0M8%

Related Comparisons